ENDPOINTS

Corcept shares soar after Phase 3 win in ovarian cancer

Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survival outcomes in a late-stage test in patients with a challenging form of ovarian cancer, sending its shares up 76% at market open on Monday. The California ...

Mar 31, 2025 - 17:52
 0
Corcept shares soar after Phase 3 win in ovarian cancer
Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survival outcomes in a late-stage test in patients with a challenging form of ovarian cancer, sending its shares up 76% at market open on Monday. The California ...
Read More

Tags:

Previous Article

Ultra-Light Bespoke E-Bike Weighs Just 21 Pounds

Next Article

University High Triumphs at JPL-Hosted Ocean Sciences Bowl

Related Posts

Merck opens billion-dollar facility to make bladder cancer immunotherapy

Merck opens billion-dollar facility to make bladder can...

Mar 11, 2025  0

Alnylam appears to win approval for ATTR-CM, setting up competition with Pfizer and BridgeBio

Alnylam appears to win approval for ATTR-CM, setting up...

Mar 20, 2025  0

Exelixis’ cancer drug wins approval for neuroendocrine tumors

Exelixis’ cancer drug wins approval for neuroendocrine ...

Mar 26, 2025  0